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2. 
Abstract 
 
Context 
In addition to the effectiveness of terminal care, policy makers and health care payers are 
concerned about the costs of treating terminal patients in a context of spiralling health 
care costs and limited resources. 
Objectives 
This article aims to review the international literature on the costs of treating terminal 
patients.  
Methods 
Studies were identified by searching PubMed, Centre for Reviews and Dissemination 
databases, Cochrane Database, and EconLit up to April 2009. Studies were included that 
contrasted costs in different healthcare settings and that compared palliative care with 
alternative therapeutic approaches for terminal patients.  
Results 
The few studies that focused on treatment of terminal patients across health care settings 
showed that hospitalisation costs represent the principal component of palliative care 
costs. In the hospital setting, palliative care tends to be cheaper than usual care or care 
delivered in units other than the palliative care unit. Palliative care costs depend on 
patient characteristics such as diagnosis, status of disease and age. Also, different care 
models appear to target different patient groups and offer varied packages of services. 
Finally, there is some evidence pointing to cost advantages of palliative care at home as 
3. 
compared to alternative care models, although this needs to be corroborated by further 
research.  
Conclusion 
Different approaches to delivering palliative care are not substitutes of each other and, 
thus, have different costs. From a cost perspective, hospitals need to pay attention to 
admitting patients to the palliative care unit at the right time. 
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4. 
Introduction 
 
Treatment of terminal patients aims to improve the quality of life of patients with life-
limiting conditions by emphasizing relief from pain and symptoms, by involving their 
family and friends, and by adopting a holistic, non-curative focus. However, health care 
systems have a limited ability to meet the needs of terminal patients and to keep a balance 
between costs and quality of care at the end of life. In addition to the effectiveness of care 
models for terminal patients, policy makers and health care payers are concerned about 
the costs of treating terminal patients in a context of spiralling health care costs and 
limited resources.  
 
To date, little is known about the costs of treating terminal patients in terms of the level 
of costs, the distribution of costs between health care settings, and the cost drivers of 
treating terminal patients. First, few studies have quantified the economic burden of 
treating terminal patients. For instance, the Independent Sickness Funds in Belgium 
estimated that expenditure on palliative care increased from 42 million € in 2003 to 77 
million € in 2007, an annual average increase of 16% (1). Palliative care accounted for 
0.4% of Belgian health expenditure in 2007. Second, it is important to have insight into 
the distribution of costs of treating terminal patients between health care settings. For 
instance, public expenditure on ambulatory palliative care was incurred by home nursing 
(61% of expenditure), mobile palliative support teams (13%), the palliative home care 
allowance (12%), nursing homes (11%), and the abolition of the patient co-payment for 
consultation by the general practitioner (3%) in Belgium in 2003 (2). Third, there is little 
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evidence on the cost drivers of treating terminal patients. For instance, a Belgian 
retrospective analysis found that hospitalisation during the three final months of life was 
less likely if, amongst other things, the general practitioner provided palliative care and if 
treatment had a palliative rather than a curative focus (3).  
 
The aim of this article is to review the international literature on the costs of treating 
terminal patients. The literature review was undertaken as part of a larger study on 
palliative care in Belgium commissioned by the Belgian Healthcare Knowledge Centre. 
The article focuses on the level, distribution and drivers of costs of treating terminal 
patients, and appraises the methodological quality of cost studies. The cost estimates and 
methodological perspective provided by this article may serve to determine priorities for 
and inform future research on terminal patients, and may be used in future economic 
evaluations exploring the cost-effectiveness of various care models for terminal patients. 
 
Methods 
 
Search strategy 
 
Studies were identified by searching PubMed, Centre for Reviews and Dissemination 
databases (Database of Abstracts of Reviews of Effects, National Health Service 
Economic Evaluation Database, and Health Technology Assessments Database), 
Cochrane Database of Systematic Reviews, and EconLit up to April 2009. Additionally, 
the bibliography of included studies was checked for other relevant studies. Search terms 
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included ‘palliative care’, ‘end of life’, ‘terminal patients’, ‘economics’, ‘costs’, 
‘economic burden’, ‘cost analysis’ alone and in combination with each other. 
 
The review was limited to studies published between 2000 and 2009.  Earlier articles 
were considered of limited relevance because changes in the organisation and financing 
of palliative care over time are likely to influence cost estimates.  There was no limitation 
on the language of the article. 
 
Inclusion/exclusion criteria 
 
The literature review targeted studies on the costs of treating terminal patients. Inclusion 
was limited to studies that contrasted costs in different healthcare settings, and to studies 
that compared palliative care with alternative therapeutic approaches for terminal 
patients. Studies that analyzed costs at end of life in general, but did not focus 
specifically on terminal patients were excluded. Our review did not incorporate economic 
evaluations investigating the cost-effectiveness of various therapeutic approaches for 
terminal patients. Another exclusion criterion was studies that failed to convert health 
care resource utilization into costs. 
 
Inclusion was restricted to articles published in peer-reviewed journals. Congress 
abstracts were not considered because they do not provide sufficient details of 
methodology and results. 
 
7. 
Data analysis 
 
To compare costs between studies, costs were actualized to 2007 values using a rate of 
inflation based on the evolution of the Consumer Price Index. Costs were converted using 
purchasing power parities for Belgium, i.e. market exchange rates adjusted for 
differences in purchasing power between countries and Belgium.  
 
It was not appropriate to synthesise cost estimates of treating terminal patients across 
studies due to the heterogeneity of the primary studies. This heterogeneity derives from 
the fact that the health care setting; type of hospital and hospital unit; nature and content 
of palliative care and usual care; time horizon of cost assessment; cost measures; and 
study design varied between cost studies. There was insufficient common ground for 
pooling cost estimates that would permit quantitative summarization and, hence, results 
are presented for each cost study separately. 
 
Assessment of methodological quality 
 
A qualitative appraisal was carried out of the methodological quality of cost studies. An 
appraisal form was filled in by the lead author for each study focusing on study sample, 
data sources, methods of data collection, scope of included costs and time horizon (4). 
With respect to the sample, studies can be based on a representative national sample or 
enroll a specific group of patients. Data can be collected prospectively / retrospectively 
from patient medical records, a survey, a claims database or the literature. Cost studies 
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can be designed as a case series following up terminal patients, a case-control study 
comparing terminal patients with control patients, or a cohort study contrasting treatment 
approaches or health care settings for terminal patients. Studies can measure direct health 
care costs (e.g. medicines, surgical procedures, visits to health care providers, 
hospitalization), direct non-health care costs (e.g. transportation to the health care 
provider), and indirect costs arising from productivity loss. Estimates can be presented as 
charges based on official list prices or costs based on actual resource use. Finally, the 
time horizon was identified over which costs of treating terminal patients were measured. 
 
Results 
 
Few studies have investigated the costs of treating terminal patients: the researchers 
identified 56 papers, for which the abstract was assessed. Based on the abstract, nine 
papers were excluded because they either measured costs at the end of life rather than 
costs of terminal patients, they quantified health care resource utilization but did not 
convert it into costs, or they carried out an economic evaluation rather than a cost study. 
The full manuscript of the remaining 47 articles was assessed. Of these articles, 32 
articles were excluded for the same reasons as stated previously, and 15 articles were 
included in the review (see Figure 1).  
 
Existing studies make up a disparate and varied body of evidence focusing on different 
aspects, including costs of treating terminal patients across health care settings, costs of 
various treatment approaches (e.g. palliative care, usual care) in different types of 
9. 
hospitals (e.g. acute care hospital, university hospital) and in different types of hospital 
units (e.g. palliative care unit, other hospital unit), and costs of different models to treat 
terminal patients at home. No study was identified that measured costs of treating 
terminal patients in nursing homes. The characteristics of existing studies have been 
summarised in Table 1.    
 
Costs of treating terminal patients across health care settings 
 
Studies across health care settings are of particular importance as terminal patients often 
experience transitions between settings i.e. hospital, outpatient and home care settings. 
Still this review only identified two studies that compared the costs in those different 
health care settings. A prospective, multi-centre study undertook a cost analysis of 80% 
of Spanish palliative care services (5). Spanish palliative care services are diverse and 
include acute bed units in general hospitals, specialist cancer units, nursing homes, 
hospital support teams, and home care support teams. Cost data were gathered on 372 
patients during the last six weeks of life by means of a weekly structured telephone 
interview. Hospital unit costs were derived from published sources, but unit costs for care 
other than hospital care were based on assumptions. Total costs per patient amounted to 
2,774 € and could be broken down into hospitalisation costs of 2,390 € per patient and 
other costs (i.e. outpatient clinic and home care) of 384 € per patient. Cost estimates may 
have been influenced by the social context and the health care system in Spain. For 
instance, the high number of home care visits reflects the high emphasis placed on home 
care teams and the active support by family members in Spain. 
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A British study calculated palliative care costs for different types of advanced cancer 
patients from the time that they started strong opioid treatment until death (6). The study 
enrolled 547 patients and was conducted from the perspective of the National Health 
Service. The authors considered costs of drugs, general practitioner visits, palliative care 
physician visits, and hospital admissions, but did not include costs of specialist nursing 
and hospital-based prescribing. Mean costs of palliative care amounted to 3,418 € for 
colon cancer; 4,672 € for breast cancer; 4,936 € for lung cancer; 5,069 € for uterus 
cancer; 6,577 € for stomach/oesophagus cancer; 7,086 € for prostate cancer; and 9,014 € 
for ovarian cancer. However, this study did not control for confounding factors (e.g. 
patient age, survival time, time to start of palliative care, duration of palliative care) 
which differed between cancer types. Hospitalisation was the key driver of costs, 
accounting for 35%-77% of palliative care costs. The authors concluded that palliative 
care costs vary between different types of advanced cancer patients.  
 
Costs of treating terminal patients in hospital 
 
A case series measured and identified the determinants of palliative care costs of 
hepatocellular carcinoma in Hong Kong (7). Two hundred and four patients were 
enrolled. The analysis was undertaken from a societal perspective, including costs of 
formal and informal services incurred by payers, caregivers and patients. The mean cost 
for formal health services per patient amounted to 3,546 € from first hospitalisation until 
death. A regression analysis showed that severity and chemotherapy increased formal 
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service costs per day, but patient age, number of days of observation and survivorship 
decreased formal service costs per day. This study did not include a control group of 
patients and results were specific to patients suffering from inoperable hepatocellular 
carcinoma. 
  
A prospective cohort study calculated costs of palliative care in two hospitals providing 
general medicine, surgical and obstetric care and in two hospitals offering extended care 
and rehabilitation in France (8). Predictive factors of palliative care costs were identified. 
The analysis enrolled 119 patients. Total costs per day amounted to 493 € for all patients, 
547 € for patients admitted to hospitals providing general medicine, and 440 € for 
patients admitted to hospitals providing extended care. The cost difference between the 
two types of hospital was explained by the fact that palliative care units in hospitals 
providing general medicine employed more staff. Total costs consisted of staff salaries 
(62% of costs), logistical expenses (23%), overheads (5%), medicines (5%), depreciation 
of heavy equipment (3%), disposable devices (1%), and diagnostic tests (1%). The 
following variables were predictive of higher costs: degree of anxiety of patients and 
their family; proximity of death; extreme dependence; ear, nose and throat cancer; young 
patient age; and the provision of certain procedures. Although this study was carried out 
in a limited number of palliative care units and enrolled a small number of patients, the 
authors concluded that the population of patients in palliative care units is not 
homogeneous from an economic point of view. In other words, palliative care unit costs 
depend on patient characteristics. 
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A US case-control study included 38 patients admitted to a hospital palliative care unit 
and 38 patients who died outside the palliative care unit and who were cared for by other 
medical or surgical teams (9). The palliative care unit was a dedicated 11-bed inpatient 
unit staffed by a high-volume specialist team using standardised care. The analysis 
collected data on charges (based on official list prices) and on costs (based on actual 
resource use). The palliative care unit generated lower daily charges (-59%) and lower 
daily costs (-57%). Some of these savings originated from discontinuing costly 
interventions once patients were clearly identified as dying. It was not clear to what 
extent the high volume of the palliative care unit produced economies of scale and 
lowered costs. 
 
A cohort study calculated costs of patients admitted to a hospital palliative care unit as 
compared to patients admitted to an intensive care unit or any unit other than palliative 
care in the United States (10). In addition to this, approaches to controlling costs of a 
palliative care unit were identified. The cost per day for hospitalised patients during the 
last 20 days leading to their death was significantly lower on the palliative care unit than 
on intensive care units and non-palliative care units. As a consequence, the authors 
emphasised the importance of admitting patients to the palliative care unit at the right 
time with a view to containing costs. Approaches to controlling costs included: a) 
appropriate admissions to the palliative care unit; b) direct admissions from the 
emergency department to the palliative care unit; and c) transfer of patients from more 
costly sites of care (e.g. intensive care unit) to the palliative care unit. Finally, palliative 
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care unit costs diminished as a result of better coordination of care and elimination of 
unnecessary tests. 
 
A retrospective, observational study of 314 veterans in the United States compared costs 
of palliative care with those of usual care during a terminal hospitalization (11). Inpatient 
costs were broken down into ancillary (laboratory and radiology) costs and pharmacy 
costs. Hospital palliative care was associated with lower inpatient costs per day (-245 €) 
and lower ancillary costs per day (-100 €). There was no difference in pharmacy costs 
between palliative care and usual care. It should be noted that the specific organisation 
and financing of health care for veterans in the United States might hinder the 
transferability of those results to other health care settings.   
 
The author of a US study adopted a case-control design to compare charges of 164 
patients who received an inpatient palliative care consultation with charges of 152 
inpatients who did not (12). As such, this study assessed a consultative palliative care 
programme rather than a programme providing overall care. The measurement of charges 
in lieu of costs is a limitation of this analysis because charges may not have a consistent 
relationship with costs. Mean daily charges amounted to 4,043 € for cases and 4,358 € for 
control patients. Daily charges for consultative palliative care related to supplies and 
equipment (29% of charges), pharmacy (28%), laboratory and imaging (22%), room and 
board (20%), and other therapy (2%). Patients who received a consultation because of 
non-physical symptoms (e.g. care planning, personal concerns, spiritual concerns) 
generated higher charges.  
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A similar US study investigated costs of patients who received an inpatient palliative care 
consultation with costs of inpatients who received usual care (13). However, this study 
enrolled a larger sample of patients (4,908 palliative care patients and 20,551 usual care 
patients), matched control patients to cases, included patients from eight diverse 
hospitals, and measured costs rather than charges. Also, this study distinguished between 
patients who were discharged alive and patients who died. Hospital costs related to costs 
of the intensive care unit, pharmacy, laboratory, and diagnostic imaging tests. Palliative 
care patients discharged alive had net savings of 1,684 € in costs per admission and 277 € 
in costs per day. Cost savings originated from reductions in laboratory and intensive care 
unit costs as compared with usual care patients. Palliative care patients who died had net 
savings of 4,872 € in costs per admission and 371 € in costs per day as a result of 
reductions in pharmacy, laboratory, and intensive care unit costs as compared with usual 
care patients. The authors concluded that hospital palliative care consultation teams 
generate savings. 
 
Costs of treating terminal patients at home 
 
The costs of palliative care at home were computed in an Italian case series (14). The 
home care service provided a telephone hotline to patients and the team consisted of 
oncologists and nurses with additional skills in cancer nursing. This service was restricted 
to patients with an estimated life span of two months or less as estimated by clinicians. 
Costs of the home care service amounted to 39.9 € per patient per day. This figure 
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covered costs of the support and coordination team (8.3 €), medicines (14.4 €), general 
practice fees (5.7 €), medical examinations (5.0 €), nursing (4.2 €), supplies (1.6 €) and 
specialist consultations (0.5 €).  
 
An Italian retrospective, observational study analysed the costs of a home care 
programme according to the disease status and life expectancy of patients with 
haematological malignancies (15). One hundred and forty-four patients were assigned to 
one of the following groups: a) terminal phase requiring palliative care (89 patients); b) 
advanced phase requiring palliative care (31 patients); c) chronic phase requiring 
supportive therapy (9 patients); and d) curable phase requiring supportive therapy (15 
patients). A multi-professional home care team provided for around the clock support and 
routine visits to patients by staff. The team consisted of haematologists, nurses, 
psychologists and social workers. The general practitioner was also involved. Mean 
monthly costs of health care providers, materials and medicines, transfusion support, 
laboratory and diagnostic procedures amounted to 4,533 € for the terminal phase; 2,468 € 
for the advanced phase; 1,594 € for the chronic phase; and 4,270 € for the curable phase. 
Higher costs of the terminal phase and of the curable phase could be attributed to the 
higher number of medical and nursing visits, and transfusions required by such patients. 
This study showed that home care costs depend on disease status of patients. However, 
other variables that may influence home care costs, such as age and diagnosis of patients, 
were not controlled for. Also, the number of patients included in some disease status 
groups was relatively small.  
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A retrospective, observational study enrolled all patients undergoing palliative care who 
died from cancer in a Spanish town in 1998 (16). Patients received either standard care 
management (111 patients) or home care support by a specialised team (44 patients). The 
perspective was that of the Catalan Health Service and the time horizon was one month. 
Mean costs per patient were lower for patients receiving home support than for patients 
receiving standard care management (-683 €). This cost advantage of home support 
originated from lower costs of hospitalisation, outpatient care use, emergency department 
visits, and days of stay in palliative care units in nursing homes. However, the authors 
could not rule out selection bias as possible differences in characteristics between patient 
groups (e.g. illness severity) may influence cost estimates. Cost estimates also reflected 
the practices of one specialised home support team and may not be applicable to other 
teams.  
 
An Israeli analysis compared health care costs of two models of delivering palliative care 
at home to terminally-ill patients during their last year of life (17). Costs of 120 patients 
receiving home-specialised palliative care services were contrasted with those of 515 
patients receiving home non-specialised palliative care services. No detailed description 
of home (non-)specialised palliative care services was provided by the authors. Health 
care costs of home-specialised services were 30% lower than those of non-specialised 
services during the last year of life. The cost difference increased nearer the time of 
death. Lower costs of home-specialised services could be attributed to lower costs of 
hospitalisations and of oncology treatments. The authors argued that this may be 
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explained by the nature of the specialised palliative care approach which provides for 
around the clock support and routine visits to patients by staff. 
 
The cost impact of two new services allowing patients to be cared for at home was 
explored by a retrospective before-and-after study in England (18). The services 
consisted of a rapid response team and discharge community link nurses. The rapid 
response team is a community-based team that makes patient visits during out-of-hours 
periods and that provides support to patients over the telephone. The discharge nurses 
facilitate speedy discharge of patients with complex needs who are receiving palliative 
care. Cost data related to 40 cancer patients receiving palliative care prior to 
implementation of these services and 40 comparable patients who accessed programme 
services. The mean cost of acute and community services amounted to 8,888 € for 
patients who accessed programme services and 8,760 € for patients who did not. The 
authors did not exclude the possibility that programme services were accessed by patients 
who are able to and wish to die at home, thus introducing potential selection bias. 
 
A British cohort study compared costs of 173 patients attending one of five palliative day 
care centres with those of 53 patients who received support from specialist palliative 
home care teams (19). The authors did not provide a detailed description of palliative day 
care and did not report costs of palliative home care. Data were collected by means of a 
questionnaire asking patients to report costs of health and social care use in the previous 
four weeks. No statistical analyses were undertaken due to the small sample size and 
sample attrition. Costs of palliative day care amounted to 106 € per person per day, 
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increasing to 146 € if unpaid resources (e.g. volunteers) were included. The authors also 
found that patients who attend palliative day care access a different package of care than 
those who do not. This may reflect differences in characteristics of these two groups of 
patients and imply that palliative day care and palliative home care are not substitutes. 
 
Discussion 
 
The body of evidence on the costs of treating terminal patients was small and varied. 
Although palliative care requires a multidimensional and interdisciplinary approach, few 
studies calculated palliative care costs across health care settings. These studies showed 
that hospitalisation costs represent the principal component of palliative care costs. A 
number of studies focused on palliative care in hospitals. The results consistently 
indicated that palliative care is cheaper than usual care or care delivered in hospital units 
other than the palliative care unit. Therefore, our analysis supports the policy 
recommendation that hospitals need to pay attention to admitting patients to the palliative 
care unit at the right time from a cost perspective. Also, there is some evidence pointing 
to cost advantages of palliative care at home as compared to alternative care models, 
although this needs to be corroborated by further research. If palliative care is viewed as a 
component of a broader care programme (e.g. a comprehensive oncology programme), no 
study has examined the cost impact of palliative care on the care programme. 
 
Cost studies vary in terms of how a terminal patient is defined. This variety in definitions 
is also observed in the epidemiological and clinical literature. Based on a literature 
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review, different approaches have been proposed to define the ‘terminal’ status: a) by the 
patient ‘readiness’ i.e. the patient is ready to address terminal issues when he/she is aware 
of his/her prognosis; b) by the severity of illness: ‘Is this patient sick enough that it would 
not be a surprise if he or she would die within 6 months (or 3 or 12 months)?’; and c) by 
the prognosis expressed by the physician as the risk of dying at a time in the future (20). 
Other authors have identified terminal patients by adding the content of care given: when 
curative or life-prolonging treatments are decided not to be pursued (21). Given the 
observed variety of definitions, our analysis did not propose a definition of a ‘terminal 
patient’ as a criterion to include/exclude cost studies, but summarized the available 
studies on terminal patients, recognizing that they used different definitions. This variety 
in definitions implies that inclusion/exclusion criteria and, hence, cost estimates differ 
between studies. 
 
The reader must be careful when comparing costs of treating terminal patients between 
studies for a number of reasons (22). First, the organisation and financing of health care 
systems vary between countries, implying that therapeutic services, their availability and 
associated costs differ. Second, as stated above, the definition of a terminal patient differs 
between studies. Third, the definition, nature and content of palliative care and usual care 
vary between studies. Fourth, studies generally did not consider patient out of pocket 
expenses, which vary between countries. 
 
Caution needs to be exercised when comparing the costs of different approaches to 
delivering palliative care to terminal patients. This is because the results of the literature 
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review indicate that palliative care costs depend on patient characteristics such as 
diagnosis, status of disease and age. The population of patients receiving palliative care is 
heterogeneous from a cost perspective. Also, different care models appear to target 
different patient groups and offer varied packages of services. This implies that different 
approaches to delivering palliative care are not substitutes of each other.  
 
The literature on the costs of treating terminal patients suffers from a number of 
methodological shortcomings. In the absence of randomised controlled trials, selection 
bias where patients self-select into a specific care model is an issue that is likely to 
influence cost estimates. Some sample sizes were too limited to draw generalisable 
conclusions. A combination of survey and claims data was used in studies to obtain 
information about the costs of treating terminal patients. The reliability of survey data is 
hindered by patients’ ability to recall health resource utilization and costs. Claims data 
may suffer from missing data and incorrect coding of claims. Studies enrolling a specific 
group of patients tend to be carried out prospectively using survey data. This type of 
analysis can be considered to be more reliable than studies based on a retrospective 
analysis of claims databases. Cost estimates were derived for specific patient samples and 
are unlikely to be applicable to the population of terminal patients.  
 
Studies need to move away from using charge data based on official list prices towards 
measuring costs based on actual resource use. This is because, for instance, charges for 
treating terminal patients in hospital may not accurately reflect actual expenditure on 
administration, billing, capital depreciation, maintenance, laundry and other hospital 
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services. Alternatively, in studies that measure charges, these need to be converted into 
costs by means of cost-to-charge ratios. Such adjustment by cost-to-charge ratios is 
regularly used in cost studies set in the United States (4). 
 
The scope of included costs was generally restricted to direct health care costs associated 
with treating terminal patients. This refers to costs of medicines, contacts with health care 
professionals and hospitalization. Table 2 identifies the major cost items that need to be 
considered when calculating the costs of treating terminal patients from a societal 
perspective. In addition to direct health care costs, studies need to focus on eliciting direct 
non-health care costs associated with transportation to the health care professional and 
indirect costs arising from lost productivity. With respect to the latter, attention needs to 
be paid to calculating the indirect costs of reduced ability to attend school, work or carry 
out usual daily activities. 
 
There was substantial variation between studies in how an episode of care was defined 
and in the time horizon over which costs were measured. The majority of studies 
quantified costs over a fixed time period prior to death or from the start of a specific 
health care service (e.g. hospitalization) until the time of death. In practice, this meant 
that the time horizon could range from 20 days to two years. Other studies focused on a 
specific hospitalization episode. Ideally, costs need to be computed from the time of 
diagnosis of a terminal patient until the time of death.  
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Future studies need to set up a prospective collection of primary data on healthcare 
resource use and costs of treating terminal patients. This type of analysis can be 
considered to be more reliable than retrospective analyses of patient medical records or 
claims databases. Alternatively, modeling approaches can be considered that are based on 
high-quality data, closely reflect real-life practice and the evolution of terminal patients, 
and test the robustness of cost estimates through extensive sensitivity analyses.  
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26. 
Table 1. Characteristics of studies measuring costs of terminal patients 
Sample Perspective Interventions Data collection Design Scope of costs Time 
horizon 
Year of 
costing 
Costs Ref 
Costs of treating terminal patients across health care settings 
 
372 patients National Health 
Service 
Palliative care 
services across 
hospital, outpatient, 
home care settings 
 
Prospective, 
multi-centre 
analysis of 
interview data 
Case 
series 
Health care 
costs  
Last 6 
weeks of 
life 
2001 Total costs per patient amounted to 2,774 €: 
hospitalisation costs of 2,390 € and other costs (i.e. 
outpatient clinic and home care) of 384 €. 
(5) 
547 patients 
with advanced 
cancer 
National Health 
Service 
Palliative care 
services across 
hospital, outpatient 
and home care 
settings 
Retrospective 
analysis of 
claims data 
Case 
series 
based on 
modeling 
Health care 
costs  
From start 
of opioid 
treatment 
until death 
2001 Mean costs of palliative care amounted to 3,418 € 
for colon cancer; 4,672 € for breast cancer; 4,936 € 
for lung cancer; 5,069 € for uterus cancer; 6,577 € 
for stomach/oesophagus cancer; 7,086 € for 
prostate cancer; and 9,014 € for ovarian cancer. 
Hospitalisation accounted for 35%-77% of 
palliative care costs. 
 
(6) 
Costs of treating terminal patients  in hospital 
 
204 patients 
with 
hepatocellular 
carcinoma 
Society Palliative care 
services 
Prospective 
analysis of 
interview data 
Case 
series 
Health care 
costs (hospital 
and outpatient 
care), costs of 
informal 
services, 
indirect costs 
 
From first 
hospitaliz
ation until 
death 
1998 Mean cost for formal health services per patient 
amounted to 3,546 €. Severity and chemotherapy 
increased formal service costs per day, but patient 
age, number of days of observation and 
survivorship decreased formal service costs per 
day. 
 
(7) 
119 patients Hospital Palliative care in two 
hospitals providing 
general medicine, 
surgical and obstetric 
care; and in two 
hospitals offering 
extended care and 
rehabilitation. 
Prospective 
analysis of 
survey data 
Cohort 
study 
Hospital costs From 
hospitaliz
ation until 
death 
2000 Total costs per day amounted to 493 € for all 
patients, 547 € for patients admitted to hospitals 
providing general medicine, and 440 € for patients 
admitted to hospitals providing extended care. 
Degree of anxiety of patients and their family; 
proximity of death; extreme dependence; ear, nose 
and throat cancer; young patient age; and the 
provision of certain procedures increased costs. 
 
(8) 
 
 
 
27. 
Sample Perspective Interventions Data collection Design Scope of costs Time 
horizon 
Year of 
costing 
Costs Ref 
76 patients Hospital Care in palliative 
unit; care outside 
palliative unit 
provided by other 
medical or surgical 
teams. 
 
Retrospective 
analysis of 
claims data 
Matched 
case-
control 
study 
Hospital costs First 6 
months 
after 
palliative 
unit 
opened 
2000 The palliative unit generated lower daily charges (-
59%) and lower daily costs (-57%). 
(9) 
1,744 patients Hospital Care in palliative 
unit; care in any unit 
other than palliative 
unit. 
 
Retrospective 
analysis of 
claims data 
Cohort 
study 
Hospital costs Last 20 
days of 
life 
2004 The cost per day was lower on the palliative care 
unit than on any other unit. Admitting patients to 
the palliative care unit at the right time is important 
to contain costs. Palliative care unit costs 
diminished due to better coordination of care and 
elimination of unnecessary tests.  
 
(10) 
314 veterans Hospital Palliative care or 
usual care 
Retrospective 
analysis of 
claims data 
 
Cohort 
study 
Hospital costs Terminal 
hospitaliz
ation 
 
2003 Hospital palliative care was associated with lower 
inpatient costs per day (-245 €) and lower ancillary 
costs per day (-100 €). There was no difference in 
pharmacy costs between palliative care and usual 
care. 
 
(11) 
25,459 
patients 
 
Hospital Consultative 
palliative care 
programme versus 
usual care 
 
Retrospective 
analysis of 
claims data 
Matched 
case-
control 
study 
 
Hospital costs 30 days 2004 Palliative care patients discharged alive had net 
savings of 1,684 € in costs per admission and 277 
€ in costs per day compared with usual care 
patients. Palliative care patients who died had net 
savings of 4,872 € in costs per admission and 371 
€ in costs per day compared with usual care 
patients. 
 
(13) 
316 patients Hospital Consultative 
palliative care 
programme versus 
usual care 
 
Retrospective 
analysis of 
claims data 
Case-
control 
study 
 
Hospital costs Hospitalis
ation 
episode 
2001 Mean daily charges amounted to 4,043 € for cases 
and 4,358 € for control patients. Patients who 
received a consultation because of non-physical 
symptoms (e.g. care planning, personal concerns, 
spiritual concerns) had higher charges. 
 
(12) 
Costs of treating terminal patients at home 
 
256 patients National Health 
Service 
Home care service 
consisted of 
telephone hotline and 
team of oncologists 
and nurses. 
Prospective 
analysis 
Case 
series 
Health care 
costs 
Last 2 
months of 
life 
 
2002 Costs of the home care service amounted to 39.9 € 
per patient per day. This figure covered costs of 
support and coordination team (8.3 €), medicines 
(14.4 €), general practice fees (5.7 €), medical 
examinations (5.0 €), nursing (4.2 €), supplies (1.6 
€) and specialist consultations (0.5 €). 
(14) 
28. 
Sample Perspective Interventions Data collection Design Scope of costs Time 
horizon 
Year of 
costing 
Costs Ref 
144 patients 
with 
haematologic 
malignancies 
 
National Health 
Service 
Home care service 
according to disease 
status: terminal phase 
requiring palliative 
care; advanced phase 
requiring palliative 
care; chronic phase 
requiring supportive 
therapy; curable 
phase requiring 
supportive therapy.  
 
Retrospective 
analysis of 
clinical records 
and claims data 
 
Cohort 
study 
Health care 
costs 
2 years 2005 Mean monthly costs of health care providers, 
materials and medicines, transfusional support, 
laboratory and diagnostic procedures amounted to 
4,533 € for the terminal phase; 2,468 € for the 
advanced phase; 1,594 € for the chronic phase; and 
4,270 € for the curable phase. 
(15) 
155 patients 
with cancer 
National Health 
Service 
 
Standard care 
management or home 
care support by 
specialized team. 
 
Retrospective 
analysis of 
claims data 
Cohort 
study 
Health care 
costs 
1 month 1998 Mean costs per patient were lower for patients 
receiving home support than for patients receiving 
standard care management (-683 €). This cost 
advantage originated from lower costs of 
hospitalisation, outpatient care use, emergency 
department visits, and days of stay in palliative 
care units in nursing homes. 
 
(16) 
635 patients Health 
maintenance 
organization 
 
Home-specialised 
palliative care 
services or usual 
care. 
 
Retrospective 
analysis of 
claims data 
Cohort 
study 
Health care 
costs 
Last year 
of life 
 
2000 Health care costs of home-specialised services 
were 30% lower than those of usual care. The cost 
difference increased nearer time of death. Lower 
costs of home-specialised services were due to 
lower costs of hospitalisations and of oncology 
treatments. 
 
(17) 
80 patients National Health 
Service 
Rapid response team 
or discharge 
community link 
nurses. 
 
Retrospective 
analysis of 
claims data 
Before-
and-after 
study 
Health care 
costs 
From 
access to 
service 
until death 
2006 The mean cost of acute and community services 
amounted to 8,888 € for patients who accessed 
programme services and 8,760 € for patients who 
did not. 
 
(18) 
226 patients National Health 
Service 
 
Palliative day care 
centre or support 
from specialist 
palliative home care 
team. 
 
Prospective 
analysis of 
survey data 
Cohort 
study 
 
Health and 
social care costs 
4 weeks 1999 Costs of palliative day care amounted to 106 € per 
person per day, increasing to 146 € if unpaid 
resources (e.g. volunteers) were included. 
(19) 
 
 
29. 
Table 2. Items to consider when calculating costs of treating terminal patients 
Direct health care costs Direct non-health 
care costs 
Indirect costs 
Medication Health care 
providers 
Other   
… General 
practitioner 
 
Specialist 
physician 
 
Psychologists 
 
Nurse 
 
Diagnostic tests 
 
Social worker 
 
Accident and 
Emergency visit 
 
Alternative 
medicine 
 
Transportation to 
health care 
provider 
 
Child care costs 
 
Home adaptations 
 
Time lost from 
school 
 
Time lost from 
work 
 
Reduced ability to 
carry out usual 
daily activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30. 
Figure 1. Flow chart of literature search 
 
56 articles identified   
   Exclusion because of: 
- costs at end of life rather than costs 
of terminal patients; 
- health care resource utilisation not 
converted into costs; 
- economic evaluation 
47 full articles retrieved  
   
15 articles included   
 
 
 
